Thomson Reuters Annual Pharmaceutical Factbook Reveals Key Insights into Current Trends
(Thomson Reuters ONE) -
Fewer projects with higher success rates show focus on quality paying off
London, UK, 26 June 2012 - The Intellectual Property & Science division of
Thomson Reuters released its annual synopsis of pharmaceutical industry trends
today in its 2012 Pharmaceutical R&D Factbook, compiled by CMR International, a
Thomson Reuters business. Key findings include the observation that the
pharmaceutical industry's recent emphasis on quality over quantity is working,
as evidenced by a lower number of early phase projects and fewer phase III
projects being terminated, combined with an increase in regulatory approvals.
An essential publication of pharma facts containing eleven chapters of essential
data on R&D pipeline volume, success rates, cycle times, regional comparisons,
therapeutic areas, generics and others, the Factbook provides valuable strategic
insight to pharmaceutical leaders for managing their businesses. This year's
Factbook underscores the industry's focus on drug production quality, as is
evidenced by:
* Global Pharmaceutical Sales Highest Ever: Global pharma sales reached an
all-time high of approximately $880 billion in 2011; with pharmaceutical
companies reinvesting anywhere from two percent to 25 percent of sales in
prescription drug (or "ethical drug") R&D. Nevertheless, the rate of growth
is declining as key drugs come off patent and the generic market grows
* Most New Molecular Entities (NMEs) Launched in Last Decade: The number of
NMEs launched are at a ten-year high (increasing to 31). Regulators and
payers are looking for safer, more effective and differentiated drugs given
the large influx of generics. The industry is seeing the first signs of the
response by Pharma to increased R&D hurdles in the selection of drug
candidates that are focused on diseases with high unmet medical need and, in
many cases, targeted at stratified groups of patients (so called
personalized medicine). This refocus is welcomed by the regulators and
payers as reflected by the increased number of drug launches
* Cancer treatment benefitting from advances in personalized medicine: Anti-
cancer development continues to attract the highest amount of investment
across all therapeutic areas; with recent personalized medicine advances
yielding two important oncology drug approvals in 2011 with companion
diagnostics for targeted patient populations
* A marked turn in Phase III success: In the last three years we have seen a
notable increase in phase 3 project success rates
* More targeted therapies: An increase in biologics in pharma R&D with higher
clinical success rates and slower decline from peak sales, as well as an
improvement in translating innovations in biological understanding from lab
to patient
"The pharmaceutical industry touches all of our lives, whether directly or
indirectly. Having insight into the drivers of the outcomes in Pharma R&D is
critical in planning strategies and operational improvements," said Jon Brett-
Harris, executive vice president, Thomson Reuters. "This year's Factbook
provides a unique view into the industry at a point when many pharma leaders are
developing new strategies for growth. It unveils our thought-leaders' findings
from extensive and proprietary data and is a valuable resource for clinical
operations, project management, portfolio managers, licensing executives,
venture capitalists, and pharmaceutical executives alike."
Information published in the Factbook was compiled by our Life Sciences
Professional Services team; it is based on proprietary primary sources,
competitive intelligence, and public sources covering key trends in the
pharmaceutical industry.
About CMR International
CMR International, a Thomson Reuters business, is the world leader in global
pharmaceutical R&D performance measurement. For over 15 years, CMR International
has worked with the leading global pharmaceutical companies to assess R&D
productivity and provide insights into industry trends in order to strengthen
planning and effectiveness of R&D. Since 2003, CMR International has published
the pharmaceutical R&D Factbook, an annual report for the pharmaceutical R&D
sector providing a reliable source of key reference metrics.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial and risk, legal, tax and accounting, intellectual property and science
and media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs approximately 60,000 people and operates in over 100
countries. For more information, go to www.thomsonreuters.com.
CONTACTS
Laura Gaze John Roderick
IP Solutions J. Roderick Inc.
+1.203.868.3340 +1.631.656.9736
laura.gaze(at)thomsonreuters.com john(at)jroderick.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1622123]
Unternehmensinformation / Kurzprofil:
Datum: 26.06.2012 - 14:36 Uhr
Sprache: Deutsch
News-ID 160083
Anzahl Zeichen: 6252
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 264 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thomson Reuters Annual Pharmaceutical Factbook Reveals Key Insights into Current Trends"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
